ArticleMaterials today. Bio2025
ECM characterization and 3D bioprinted models of NSCLC for investigating stiffness-dependent tumor behavior and drug response.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Super-Multiplexed Label-Free Raman Imaging Uncovers Novel Testicular Metabolic Couplings for Residual Body and Spermatogonial Differentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- 3D bioprinting for cancer modeling and drug screening.Biomarker research · 2026Review
- 3D Bioprinting for Tumor Microenvironment Reconstruction: Advances, Challenges, and Future Perspectives.Biotechnology journal · 2026Review
- Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification.Materials today. Bio · 2026Article
- Three-dimensional-bioprinted stiff matrix triggers PDAC radioresistance through histone H3 lysine 18 lactylation (H3K18la) potentiates RAD51 activation.Regenerative biomaterials · 2026Article
- Label-free molecular profiling of cancer using Raman spectroscopy: from fundamentals to clinical applications.Frontiers in oncology · 2026Review
- Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers.PloS one · 2026Article
- Comparative analysis of molecular targeted radiosensitizers in 2D and 3D cancer cell line models.Acta oncologica (Stockholm, Sweden) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heterogeneity and complex extracellular matrix (ECM) characteristics of non-small cell lung cancer (NSCLC) present significant challenges for understanding its pathological mechanisms and advancing precise treatment strategies. This study characterized the physicochemical properties of native NSCLC ECM to inform the biomimetic design of 3D models utilizing biomaterials and light-based 3D bioprinting technologies. A tunable 3D model was constructed that replicates the interfacial structures and matrix stiffness of both lung cancer tissue and adjacent normal tissue. This model elucidates the impact of matrix stiffness on cellular behaviors, including proliferation, invasion, and drug sensitivity, and delineates the role of the CCN1 gene under different mechanical conditions. Specifically, it demonstrates that a reduction in CCN1 expression within soft matrices can attenuate the migratory and proliferative capabilities of tumor cells. Furthermore, primary NSCLC patient-derived bioprinted tissues validated the model fidelity to clinical samples and its predictive potential for responses to combined chemotherapy and immunotherapy. This study establishes a versatile platform for NSCLC modeling and research, advancing biomaterial and bioprinting strategies to replicate the tumor microenvironment and optimize therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.